See more : Astron Paper & Board Mill Limited (ASTRON.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Contineum Therapeutics, Inc. Class A Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
- WestBond Enterprises Corporation (WBE.V) Income Statement Analysis – Financial Results
- Independence Realty Trust, Inc. (IRT) Income Statement Analysis – Financial Results
- Knight Therapeutics Inc. (GUD.TO) Income Statement Analysis – Financial Results
- ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ) Income Statement Analysis – Financial Results
- MEHTA SECURITIES LTD. (MEHSECU.BO) Income Statement Analysis – Financial Results
Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 50.00M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 329.00K | 0.00 |
| Gross Profit | 50.00M | -329.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% |
| Research & Development | 27.60M | 16.89M | 22.36M |
| General & Administrative | 6.32M | 5.83M | 6.29M |
| Selling & Marketing | 0.00 | -329.00K | 0.00 |
| SG&A | 6.32M | 5.50M | 6.29M |
| Other Expenses | 0.00 | -92.00K | -91.00K |
| Operating Expenses | 33.92M | 22.39M | 28.65M |
| Cost & Expenses | 33.92M | 22.72M | 28.65M |
| Interest Income | 4.61M | 761.00K | 77.00K |
| Interest Expense | 208.00K | 388.00K | 332.00K |
| Depreciation & Amortization | 195.00K | 329.00K | 325.00K |
| EBITDA | 23.57M | -23.54M | -28.34M |
| EBITDA Ratio | 47.15% | 0.00% | 0.00% |
| Operating Income | 16.08M | -22.72M | -28.65M |
| Operating Income Ratio | 32.15% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.09M | -1.53M | -354.00K |
| Income Before Tax | 23.17M | -24.25M | -29.00M |
| Income Before Tax Ratio | 46.34% | 0.00% | 0.00% |
| Income Tax Expense | 450.00K | 0.00 | 241.00K |
| Net Income | 22.72M | -24.25M | -29.00M |
| Net Income Ratio | 45.44% | 0.00% | 0.00% |
| EPS | 1.36 | -0.97 | -1.74 |
| EPS Diluted | 1.28 | -0.97 | -1.63 |
| Weighted Avg Shares Out | 16.67M | 25.13M | 16.67M |
| Weighted Avg Shares Out (Dil) | 17.76M | 25.13M | 17.76M |
CTNM Stock: 7 Things to Know as Contineum Therapeutics Starts Trading Today
Contineum Therapeutics Announces Pricing of Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports